TNI BioTech Inc Announces New Transfer Agent

TNI BioTech Inc AnnouncesNew Transfer Agent

TNI BioTech West Palm Beach Florida (TNIB – Pink)is also pleased to announce that effective as of May 24, 2012, Direct Transfer LLC replaced Signature Stock Transfer as thecompany's transfer agent and registrar for its common stock.

New TransferAgent Contact Information:

Direct TransferLLC

500 PerimeterPark Dr, Suite D

MorrisvilleNC 27560

919.481.4000– main (ext. 122)

336.817.6605– mobile

646-225-7104– fax

TA@issuerdirect.com

www.issuerdirect.com

“Establishing a relationship with anew transfer agent is one of many important and complex operational changes thecompany is in the process of making,” says Christopher Pearce, Chief FinancialOfficer. “It was important for us and for our shareholders to have a transferagent working on our behalf who could provide robust services with a high levelof competency, integrity and transparency.”

 AboutTNI BioTech, Inc.:

TNI BioTech,Inc. is a biotechnology company researching new treatments and methods fortreatment of cancer, HIV/AIDS, and certain autoimmune and other infectiousdiseases. The primary cytokine, among many others currently being studied byTNI, is methionine enkephalin (“MENK”). MENK, in both non-human studies andhuman clinical trials, has been shown to stimulate the immune system.

However, eventhough Management considers any condition that results in altered-immuneresponse a target for investigation, the Company will most likely pursueadditional investigations for MENK as a valuable candidate in the treatment ofthe following: 

·  Autoimmune states such as rheumatoid arthritis andmultiple sclerosis;

·  As an adjunct to antibiotics in the treatment ofinfectious diseases;

·  In patients undergoing chemotherapy, radiationtreatments or surgery; and

·  In wound healing, herpes viral infections, and intreatment for the elderly.

For further information www.tinbio.com

SPECIAL NOTE REGARDING FORWARD-LOOKINGSTATEMENTS: This press release includes various “forward-looking statements”within the meaning of Section 27A of the Securities Act of 1933, as amended,and Section 21E of the Securities Exchange Act of 1934, as amended, whichrepresent the Company’s expectations or beliefs concerning future events.Statements containing expressions such as “believes,” “anticipates,” “intends,”or “expects,” used in the Company's press releases and in Disclosure Statementsand Reports filed with the Over The Counter Markets through the OTC Disclosureand News Service are intended to identify forward-looking statements. Allforward-looking statements involve risks and uncertainties. Although theCompany believes its expectations are based upon reasonable assumptions withinthe bounds of its knowledge of its business and operations, there can be noassurances that actual results will not differ materially from expectedresults. The Company cautions that these and similar statements included inthis report are further qualified by important factors that could cause actualresults to differ materially from those in the forward-looking statements.Readers are cautioned not to place undue reliance on forward-looking statements,which speak only as of the date thereof. The Company undertakes no obligationto publicly release any revisions to such forward-looking statements to reflectevents or circumstances after the date hereof.

Contact: Global Investment Media

Phone: 3103536277

Investor Relations

Marlin Molinaro, 

Marmel Communications, LLC 

702-434-8692.